This move is archived. Current quotes and coverage live on the stock page.
Follow PCRX
PharmaCorp Rx Inc. has made headlines with an impressive 8% surge in stock price, thanks to strategic acquisitions and strong financial results.
In a notable turn of events, PharmaCorp Rx Inc. (PCRX.V) saw its stock price rise to CA$0.54 after an 8.00% gain in the last trading session. This increase comes amid positive news about the company's expansion strategy and financial performance.
PharmaCorp Rx Inc.
PCRX.V
PCRX.V
PharmaCorp Rx Inc.
WealthAwesomeMarket cap
$79.78M
52W high
$0.58
52W low
$0.38
1W change
-3.57%
Beta
-3.95
Analyst Price Targets
Based on analyst covering PCRX · as of Sep 17, 2026
Wall Street analysts forecast PCRX stock price to rise 64.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.67
+64.6% Upside
Current Price
C$0.41
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on PCRX's historical volatility
30-Day Vol
43.8%
Annualized
90-Day Vol
51.6%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.34
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.38 | C$0.33 – C$0.44 |
| 60 trading days | C$0.36 | C$0.29 – C$0.45 |
| 90 trading days | C$0.34 | C$0.26 – C$0.44 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should think about the implications of PharmaCorp's aggressive acquisition strategy, which could set the company up for strong growth in the competitive pharmacy sector.
8% Surge in PharmaCorp's Stock Price
PharmaCorp's stock climbed to CA$0.54, reflecting investor optimism following its strategic acquisitions.
Bull case
The recent announcement of acquiring multiple pharmacies could boost PharmaCorp's market presence and revenue streams, potentially leading to better financial stability and growth.
Bear case
Despite the positive stock movement, investors should stay cautious about the company's current negative profit margin and the risks involved with its aggressive expansion plans.
Strategic Acquisitions Fuel Growth
PharmaCorp's recent announcement about acquiring four pharmacies has caught investor interest. This strategic move not only strengthens PharmaCorp's position in the pharmacy sector but is also expected to drive revenue growth. The company reported a net income of $254,000 for Q1 2025, highlighting its potential for profitability as it expands. For more insights, check out the latest results.
Market Response and Future Outlook
The market's positive reaction to PharmaCorp's expansion strategy is clear in the stock's significant rise. However, investors should keep an eye on the company's current financial metrics, including a negative profit margin. As PharmaCorp continues to pursue its growth agenda, it will be important to monitor its execution and market conditions. For ongoing updates, visit the PharmaCorp stock page.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
